KYMERA THERAPEUTICS INC (KYMR) Stock Analyst Ratings
NASDAQ:KYMR • US5015751044
87.4 USD
+0.9 (+1.04%)
At close: Feb 20, 2026
87.4 USD
0 (0%)
After Hours: 2/20/2026, 8:00:01 PM
ChartMill assigns a Buy % Consensus number of 86% to KYMR. The Buy consensus is the weighted average rating of the current analysts ratings.
- Analysts have set a mean price target forecast of 114.77. This target is 31.32% above the current price.
- KYMR was analyzed by 29 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about KYMR.
- In the previous month the buy percentage consensus was at a similar level.
- KYMR was analyzed by 29 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2026-02-03 | BTIG | Reiterate | Buy -> Buy |
| 2026-01-28 | Barclays | Maintains | Overweight -> Overweight |
| 2026-01-15 | BTIG | Reiterate | Buy -> Buy |
| 2026-01-06 | Wolfe Research | Downgrade | Outperform -> Peer Perform |
| 2025-12-22 | B. Riley Securities | Maintains | Buy -> Buy |
| 2025-12-16 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-12-11 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-12-11 | Stephens & Co. | Maintains | Overweight -> Overweight |
| 2025-12-10 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-12-09 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2025-12-09 | BTIG | Maintains | Buy -> Buy |
| 2025-12-09 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-12-09 | Barclays | Maintains | Overweight -> Overweight |
| 2025-12-09 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-12-09 | Truist Securities | Maintains | Buy -> Buy |
| 2025-12-09 | B of A Securities | Maintains | Buy -> Buy |
| 2025-12-09 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-12-09 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2025-12-09 | Citigroup | Maintains | Buy -> Buy |
| 2025-12-09 | Jefferies | Maintains | Buy -> Buy |
| 2025-12-09 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-11-26 | Truist Securities | Maintains | Buy -> Buy |
| 2025-11-05 | Barclays | Maintains | Overweight -> Overweight |
| 2025-11-05 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-11-05 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-22 | BTIG | Maintains | Buy -> Buy |
| 2025-10-21 | Mizuho | Initiate | Outperform |
| 2025-10-17 | Citigroup | Maintains | Buy -> Buy |
| 2025-10-01 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-09-30 | Truist Securities | Maintains | Buy -> Buy |
KYMERA THERAPEUTICS INC / KYMR FAQ
Can you provide the average price target for KYMERA THERAPEUTICS INC stock?
29 analysts have analysed KYMR and the average price target is 114.77 USD. This implies a price increase of 31.32% is expected in the next year compared to the current price of 87.4.
What is the consensus rating for KYMERA THERAPEUTICS INC (KYMR) stock?
The consensus rating for KYMERA THERAPEUTICS INC (KYMR) is 86.2069 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts cover KYMERA THERAPEUTICS INC (KYMR) stock?
The number of analysts covering KYMERA THERAPEUTICS INC (KYMR) is 29.